The data are available in the Supplemental Materials that are included with the manuscript.

Introduction {#sec005}
============

Large randomized clinical trials (RCTs) provide the best evidence to justify new treatments or to identify treatments that do not improve patient outcomes. Gordon and colleagues reported that most large NHLBI-funded trials produce null results\[[@pone.0132382.ref001]\], but their analysis only considered papers published after 2000. Considering all large trials over the last 40 years, we explore whether there has been a trend toward null finding in recent years and consider potential explanations for trends in observing null outcomes.

Method {#sec006}
======

Sample of Studies {#sec007}
-----------------

We identified all large RCTs that involved drugs or supplements funded between 1970--2012. To avoid non-publication bias, we focused on large trials where non-reporting of outcomes is rare\[[@pone.0132382.ref001]\]. The search process is summarized in a PRISMA diagram ([S1 Fig](#pone.0132382.s001){ref-type="supplementary-material"}). Two independent searches were conducted to improve probability of accurately capturing all related trials--one by the study authors and the second by NHLBI. We searched three different NIH grant databases (QVR, NIH REPORTER, and CRISP) for RCTs that were primarily funded or administered by NHLBI. QVR is an internal NIH data-base, but readers can replicate our search using NIH REPORTER and CRISP which are publically available resources listing all grants and associated publications. Inclusion criteria were: RCT for studies funded from 1970--2012; grants or contracts; direct costs funded were large enough to require special authorization (\>\$500,000/ year); the word "trial" had to appear in the study objectives or abstract; and primary outcome was cardiovascular risk factor, event or death. Exclusion criteria included: project still active; no human subjects protocol required; pediatric studies; animal studies; non-RCTs (i.e. observational, cohort, case control, genetic or proteomics, measurement, basic clinical research); or interventions that did not involve a drug or supplement (i.e. behavior change, devices, surgeries). An expanded methods section is available in the Supplemental Materials.

We coded the following variables: start year (earliest funding noted), publication year of main outcome study, funded through contract or cooperative agreement from NHLBI, type of comparator (placebo, active comparator, usual care), primary outcome specified or not, CONSORT diagram included in publication, whether funding was exclusively from NIH versus joint industry/NIH funded (including industry contributed medications), and if they had listed any other significant results that were neither the primary outcomes or the side effects of the drug. In addition, we considered whether studies were registered in clinicaltrials.gov prior to publication.

Each trial was categorized as showing significant benefit, null, or significant harm for the primary outcome and for total mortality (See Tables [1](#pone.0132382.t001){ref-type="table"} and [2](#pone.0132382.t002){ref-type="table"}). Null was defined as a confidence interval for the RR that included 1.0.using a two-tailed test with alpha set at 0.05. The analysis was standardized by re-computing the relative risk (RR) with 95% confidence intervals (CI) for all trials.

10.1371/journal.pone.0132382.t001

###### Study characteristics and overall effect for main outcome and total mortality for studies not registered in ClinicalTrials.gov prior to publication.
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  Study                                                                                    Acronym                   Start Year   Pub Year   Primary Outcome (PO)                                        Primary Outcome   Total Mortality
  ---------------------------------------------------------------------------------------- ------------------------- ------------ ---------- ----------------------------------------------------------- ----------------- -----------------
  **Asymptomatic Carotid Artery Progression Study**                                        ACAPS                     1988         1994       3-year change in IMT wall of CA                             Benefit           Benefit
  **Aspiring Myocardial Infarction Study**                                                 AMIS                      1974         1980       All-cause mortality                                         Null              Null
  **Boston Area Anticoagulation Trial for Atrial Fibrillation**                            BAATAF                    1985         1990       Prevalence of stroke                                        Benefit           Benefit
  **Beta-Blocker Heart Attack Trial**                                                      BHAT                      1977         1982       All-cause mortality                                         Benefit           Benefit
  **Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation**            Carotid                   1986         1992       \>50% restenosis at 1 year                                  Null              NP
  **Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation**            CASCADE                   1987         1993       Composite of survival free of various cardiac events        Benefit           Null
  **Cardiac Arrhythmia Suppression Trial**                                                 CAST                      1986         1991       Cardiac death or arrest                                     Harm              Harm
  **Coronary Drug Project**                                                                CDP                       1965         1975       All-cause mortality                                         Null              Null
  **Coronary Intervention Study**                                                          CIS                       1971         1984       Progression of CAD                                          Null              Null
  **Cholesterol-lowering atherosclerosis study**                                           CLAS                      1979         1987       Atherosclerosis regression                                  Benefit           NR
  **Coronary Primary Prevention Trial**                                                    CPPT                      1971         1984       CHD death or definite non-fatal MI                          Null              Null
  **Familial Atherosclerosis Treatment Study**                                             FATS                      1984         1990       Regression primary artery                                   Benefit           NP
  **(Fenfluramine & Phentemrine) Cardiovascular System in Obesity: Effect of Treatment**   FEN-PHEN                  1983         1992       Weight loss                                                 Benefit           NR
  **Fish oil on blood pressure among mild hypertensive subjects**                          FISH OIL                  1983         1993       Blood pressure                                              Null              NR
  **Hypertension Control Program**                                                         HCP                       1980         1987       Normative bp                                                Benefit           NP
  **Hypertension Detection and Follow-up Program**                                         HDFP                      1971         1979       All-cause mortality                                         Benefit           Benefit
  **Hypertension Prevention Trial**                                                        HPT                       1981         1990       Composite of on medication or dbp\>90 sbp\>140              Benefit           NP
  **Potassium chloride on blood pressure in hypertensive men**                             KCL                       1983         1990       Reinstated blood pressure med                               Null              NR
  **Multicenter Investigation of Limitation of Infarct Size**                              MILIS                     1977         1984       Infarct size                                                Null              Null
  **Myocardial Infarction Triage and Intervention Trial**                                  MITIT                     1988         1993       Ranked composite of death, stroke, bleeding, infarct size   Null              Null
  **Multiple Risk Factor Intervention Trial**                                              MRFIT                     1974         1982       CHD death                                                   Null              Null
  **Immunosuppressive therapy for myocarditis**                                            MYOCARDITIS               1986         1995       Change in left ventricular infarction size                  Null              Null
  **Postmenopausal Estrogen/Progestin Interventions Study**                                PEPI                      1994         1995       Lipoproteins, blood pressure                                Benefit           NR
  **Physician's Health Study**                                                             Physicians Health Study   1981         1989       MI infarction                                               Benefit           Null
  **Stanford Coronary Risk Intervention Project**                                          SCRIP                     1983         1994       Angiographic change of diameter                             Benefit           Null
  **Systolic Hypertension in the Elderly Program**                                         SHEP                      1984         1996       Major CVD events                                            Benefit           Null
  **Studies of Left Ventricular Dysfunction**                                              SOLVD                     1975         1991       All-cause mortality                                         Benefit           Benefit
  **Late thrombolytic therapy preserves left ventricular function**                        Thrombo                   1982         1989       Change in angiographic endpoint ejection fraction           Benefit           Null
  **Thrombolysis in myocardial infarction**                                                TIMI                      1983         1985       Reperfusion                                                 Benefit           NP
  **Treatment of Mild Hypertension Study**                                                 TOMHS                     1985         1993       Major CVD events                                            Null              NR

10.1371/journal.pone.0132382.t002

###### Study characteristics and overall effect for main outcome and total mortality for studies registered in ClinicalTrials.gov prior to publication.
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  Study                                                                                                             Acronym           Start Year   Pub Year   Primary Outcome (PO)                                           Primary Outcome   Total Mortality
  ----------------------------------------------------------------------------------------------------------------- ----------------- ------------ ---------- -------------------------------------------------------------- ----------------- -----------------
  **Action to Control Cardiovascular Risk in Diabetes---Blood Pressure**                                            ACCORD-BP         2000         2010       Composite---Non-fatal MI, non-fatal stroke, CVD death          Null              Null
  **Action to Control Cardiovascular Risk in Diabetes---Diabetes**                                                  ACCORD-Diabetes   2000         2008       Major or non-fatal MI, non-fatal stroke, CVD death             Null              Harm
  **Action to Control Cardiovascular Risk in Diabetes---Lipids**                                                    Accord-Lipid      2000         2010       Major non fatal MI stroke or CVD death                         Null              Null
  **Azithromycin and Coronary Events Study**                                                                        ACES              1998         2005       Composite---death from CV, revacularization, hospitalization   Null              Null
  **Atrial Fibrillation Follow-up Investigation of Rhythm Management**                                              AFFIRM            1995         2002       All-cause mortality                                            Null              Null
  **Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides Impact on Global Health**   AIM-HIGH          2005         2011       Composite death plus events                                    Null              Null
  **Antihypertensive and Lipid-Lowering Treatment-Amlodipine**                                                      ALLHAT-BP         1993         2002       Fatal or non-fatal MI                                          Null              Null
  **Antihypertensive and Lipid-Lowering Treatment-Doxazosin**                                                       ALLHAT-DOX        1993         2000       Fatal or non-fatal MI                                          Null              Null
  **Antihypertensive and Lipid-Lowering Treatment-Pravastatin**                                                     ALLHAT-LLT        1993         2002       All cause mortality                                            Null              Null
  **Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality**                                        Alpha Omega       2005         2010       Fatal and non-fatal cardiovascular                             Null              Null
  **Enhancing Recovery in Coronary Heart Disease Patients**                                                         ENRICHD           1995         2003       Death or recurrent MI                                          Null              Null
  **Estrogen Replacement and Atherosclerosis**                                                                      ERA               1994         2000       Mean minimal coronary artery diameter                          Null              Null
  **Initial Myocardial Metabolic Enhancement During Initial Assessment and Treatment in Emergency care**            IMMEDIATE         2004         2012       Progression of ACS to MI                                       Null              Null
  **Magnesium in Coronaries (MAGIC)**                                                                               MAGIC             1998         2002       30 day all cause mortality                                     Null              Null
  **Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy**                                     PEACE             1995         2004       Death from CVD                                                 Null              Null
  **Prevention of Recurrent Venous Thromboembolism**                                                                PREVENT           1998         2003       Recurrent venous thromboembolism                               Benefit           Null
  **Stop Atherosclerosis in Native Diabetics Study**                                                                SANDS             2002         2008       Carotid artery intimal medial thickness                        Benefit           Null
  **Sudden Cardiac Death in Heart Failure Trial**                                                                   SCD-HeFT          1997         2005       Total mortality                                                Null              Null
  **Women\'s Antioxidant Cardiovascular**                                                                           WACS              1993         2007       CVD death or events                                            Null              Null
  **Women's Angiographic Vitamin and Estrogen Trial**                                                               WAVE              1996         2002       Change in minimum luminal diameter                             Null              Harm
  **Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial**                            WELL-HART         1995         2003       Change in percent stenosis                                     Null              Null
  **Women\'s Health Initiative- Estrogen**                                                                          WHI-E             1999         2004       CHD incidence                                                  Null              Null
  **Women\'s Health Initiative- Estrogen-Progestin**                                                                WHI-EP            1999         2002       CHD incidence                                                  Harm              Null
  **Women\'s Health Study- Aspirin**                                                                                WHS-ASA           1991         2005       Non-fatal MI or stroke or death from CVD                       Null              Null
  **Women\'s Health Study- Vitamin E**                                                                              WHS-E             1991         2005       Events and cardiac interventions.                              Null              Null

Results {#sec008}
=======

Among 4,089 individual years of grant funding, almost half were excluded as multiple years of the same grant and over 20% were excluded because they were single sites in multi-site trials, coordinating centers, or ancillary studies of the same trial. An additional 1,176 grant abstracts did not match our criteria and were excluded (see [S1 Table](#pone.0132382.s003){ref-type="supplementary-material"} for detailed reasons). Main outcome papers were searched for 84 trials; 10 were not published and 25 did not match search criteria and were excluded (See [S1 Fig](#pone.0132382.s001){ref-type="supplementary-material"} for the PRISMA diagram and [S1 Table](#pone.0132382.s003){ref-type="supplementary-material"} for the number of studies excluded by reason.) Following exclusions, we identified a total of 49 funded grants. Four of these grants resulted in multiple unique trials (ACCORD Blood Pressure, Diabetes, and Lipid; ALLHAT-BP, DOX, LLT; WHI Estrogen and Estrogen-Progestin, and WHS aspirin and vitamin E). A total of 55 trials were analyzed-- 30 were published prior to 2000 and 25 were published in 2000 or later (see [S2 Table](#pone.0132382.s004){ref-type="supplementary-material"} for list of included trials. A complete list of the references also appears in the Supplemental Materials).

[Fig 1](#pone.0132382.g001){ref-type="fig"} plots the relative risks of the primary outcome by the publication year of the main outcome paper. Because it was an extreme outlier, the CAST study is excluded from the figure. Prior to publication in 2000, studies often showed benefits of treatments with the notable exception of CAST (not shown in figure). Following 2000, confidence intervals for relative risk ratios included 1.0 in all cases, with the exceptions of the PREVENT and the SANDS trials (benefit) and the Women's Health Initiative (Harm). In addition, the variability in RRs was considerably reduced after the year 2000 ([Fig 2](#pone.0132382.g002){ref-type="fig"}).

![Relative risk of showing benefit or harm of treatment by year of publication for large NHLBI trials on pharmaceutical and dietary supplement interventions.\
Positive trials are indicated by the plus signs while trials showing harm are indicated by a diagonal line within a circle. Prior to 2000 when trials were not registered in clinical trials.gov, there was substantial variability in outcome. Following the imposition of the requirement that trials preregister in clinical trials.gov the relative risk on primary outcomes showed considerably less variability around 1.0.](pone.0132382.g001){#pone.0132382.g001}

![Summary of results on the primary outcome in NHLBI trials on pharmaceutical and supplement interventions that were not pre-registered in clinical trials.gov (panel A) and pre-registered in clinical trials.gov (panel B).\
Trials indicated by shading and black boxes had statistically significant effects of intervention while trials not shaded and represented by gray boxes had null effects.](pone.0132382.g002){#pone.0132382.g002}

Results for all cause mortality were similar. Prior to 2000, 24 trials reported all cause-mortality and 5 reported significant reductions in total mortality (25%), 18 were null (71%) and one (CAST) reported significant harm ([Table 3](#pone.0132382.t003){ref-type="table"}). Following the year 2000, no study showed a significant benefit for total mortality. An expanded presentation of the results in given in the online supplemental materials, including a figure summarizing results for all cause mortality.

10.1371/journal.pone.0132382.t003

###### Summary of Published Drug and Supplement NHLBI Trials, 1970--2012.
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                                            Published Pre-2000-Not Registered          Published Post-2000-Preregistered          χ^2^ for Difference in Benefit, df -1
  ----------------------------------------- ------------------------------------------ ------------------------------------------ ------------------------------------------------------
  Number of Trials                          30                                         25                                         
  Primary outcome specified in manuscript   23                                         25                                         4.75 p = .029[^d^](#t003fn004){ref-type="table-fn"}
  Consort-like diagram                      5                                          14                                         9.22 p = .0024[^d^](#t003fn004){ref-type="table-fn"}
  Control Groups                                                                                                                  001 p = .9798[^d^](#t003fn004){ref-type="table-fn"}
   Placebo                                  18                                         16                                         
   Usual Care                               9                                          7                                          
   Active Comparator                        3                                          2                                          
  Primary Outcome                                                                                                                 
   Benefit                                  17                                         2                                          12.2, p = 0.0005
   Harm                                     1                                          1                                          
   Null                                     12                                         22                                         
  Mortality                                                                                                                       
   Benefit                                  5                                          1 [^b^](#t003fn002){ref-type="table-fn"}   1.14 p = 0.286
   Harm                                     1                                          2                                          
   Null                                     13[^a^](#t003fn001){ref-type="table-fn"}   22[^c^](#t003fn003){ref-type="table-fn"}   
   Not powered                              5                                          0                                          
   Not reported                             6                                          0                                          

^a.^ The CDP trial did not show mortality benefits with the original follow-up period. If we had analyzed the subsequent follow-up trial that was not apriori, treatment with niacin would have shown a significant benefit to total mortality.

^b.^ The PREVENT study was stopped early for effectiveness seen in the primary outcome. The number of deaths reported shows a null effect on total mortality; but this study might have shown a benefit for total mortality had the full follow-up been completed. We report it here as significant but it will show as null in the meta-analyses.

^c.^ The SANDS study did not show any differences on total mortality or reduction of cardiovascular disease events. However, the treatment arm experienced significantly more adverse events. SANDS study authors concluded that there may not be favorable long-term outcomes for participants randomized to treatment.

^d.^ Chi-square test uses the Yates correction for continuity.

We considered a variety of explanations for the trend toward null results that emerged around 2000. (Detailed tables are given in online supplemental materials). One possibility is that more recent trials may have evaluated their treatment drug against clinically effective alternatives instead of placebos. We do not find this suggestion likely because 60% of the large NHLBI trials published prior to 2000 used a placebo as the comparator in contrast to 64% trials published after 2000 (see [S3 Table](#pone.0132382.s005){ref-type="supplementary-material"}). Placebos were used as the comparator at about the same rate prior to and after the year 2000 (p = .979).

To investigate the effect of industry co-sponsorship, we tabulated sponsorship for all reports. Unfortunately, industry co-sponsorship was not always reported prior to the year 2000 and journals did not uniformly require disclosure. After the year 2000, when the International Committee of Medical Journal Editors (ICMJE) asked for disclosure, it became apparent that industry co-sponsorship is very common. In our sample, 23 of 25 (92%) of the NHLBI trials published after 2000 had partial industry sponsorship or contribution of medications. All but two of these trials obtained null results. We also looked at previous financial relationships between investigators and industry. Prior to 2000, these relationships were reported in only 1 of the 30 trials (3%). Even after 2000, 28% of the studies did not include a disclosure section. But among articles that included disclosures, there was a financial consulting relationship between at least one author and industry in all (100%) of the cases. Industry influence would produce a bias in favor of positive results, so connections between investigators and industry is not a likely explanation for the trend toward null results in recent years.

We considered a variety of aspects of transparent reporting. Prior to 2000, 5 of the 30 published trials (17%) included a diagram that clearly accounted for the number of participants at each phase of the project. Following 2000, publications were significantly more likely to account for patients throughout the study: 14 of the 25 trials (56%) included such a flow diagram (χ2 = 9.22, p = 0.002). After the year 2000 all of the published papers clearly identified primary outcome variable, while the primary outcome variable was not specified in 23% of the publications prior to 2000 (χ2 = 4.75, p = 0.03).

A final explanation for the trend toward null reports is that current authors face greater constraints in reporting the results of their studies. In our review, the year 2000 marks the beginning of a natural experiment. After the year 2000, all (100%) of large NHLBI were registered prospectively in ClinicalTrials.Gov prior to publication. Prior to 2000 none of the trials (0%) were prospectively registered. Although many of the earlier studies are in the ClinicalTrials.Gov database, they were registered after the results had been published. Following the implementation of ClinicalTrials.gov, investigators were required to prospectively declare their primary and secondary outcome variables. Prior to 2000, investigators had a greater opportunity to measure a range of variables and to select the most successful outcomes when reporting their results. For trials published before the year 2000, we found that 17 out of 30 (57%) reported significant benefit for their primary outcome. In the new era where primary outcomes are prospectively declared (published post 2000), only 2 of 25 trials (8%) reported a significant benefit (χ2 = 12.2, p = 0.0005).

Prospective declaration of the primary outcome variable is important because it eliminates the possibility of selecting for reporting an outcome among many different measures included in the study. In order to investigate this issue, we looked at the statistical significance of other variables not declared as the primary outcomes for preregistered studies. Among the 25 preregistered trials published in 2000 or later, 12 reported significant, positive effects for cardiovascular-related variables other than the primary outcome. Importantly, almost half of the trials might have been able to report a positive result if they had not declared a primary outcome in advance. Had the prospective declaration of a primary outcome not have been required, it is possible that the number of positive studies post-2000 would have looked very similar to the pre-2000 period.

Discussion {#sec009}
==========

Beginning in approximately 2000, the likelihood of showing a significant benefit in large NHLBI funded studies declined. Among the explanations we evaluated, the requirement of prospective registration in Clinicaltrials.gov is most strongly associated with the observed trend toward null clinical trials. The decline is not easily explained by the increased use of active comparators or a decline in industry sponsorship. In addition to the explanations at we evaluated using reported characteristics of the trials, we considered several other suggestions.

One explanation is that newer clinical trial management methodologies remove error variance and provide more precise estimates of treatment effects. If this were the explanation, refined methodologies and greater precision should have resulted in reductions in error variance, ultimately increasing the likelihood of finding treatments effects. But the probability of finding a treatment benefit decreased rather than increased as studies became more precise. As shown in [Fig 1](#pone.0132382.g001){ref-type="fig"}, variability in trial results declined systematically around the year 2000. As a result, we do not find better trial management to be a compelling explanation for the trend toward null results.

It is widely noted that journals favor publication of statistically significant findings\[[@pone.0132382.ref002]\]. Bias in favor of publishing positive outcomes is not a likely explanation for our results. We focused on large trials because previous analyses by NHLBI reported that 97% of trials with annual budgets over \$500,000/year were published \[[@pone.0132382.ref003]\], thus removing publication bias as a rival explanation. In our analysis, 88% of the trials were published, although there may be a slight delay in the date of publication for null trials^6^. If positive trials are more likely to be published than null trials, we would have expected more positive published reports following 2000. A "file drawer" problem of suppressing null trial findings would result in over reporting positive results. Our observation of a trend toward null results goes in the opposite direction. If there is a bias, it is possible that stricter reporting standards and greater rigor in reporting requirements are suppressing the declaration of positive outcomes.

It has been argued that there have been few efficacious drugs in the pipeline\[[@pone.0132382.ref004],[@pone.0132382.ref005]\]. Since about 1998, there has been a systematic decline in the number approvals for new cardiovascular drugs\[[@pone.0132382.ref006]\]. Thus, we would expect more null trials because the rate of developing effective new principals has declined. We believe this explanation unlikely because nearly all of the trials evaluated treatments that had been previously studied. For example, all of the treatments had been approved by the US FDA and these approvals require early phase trial evidence of safety and efficacy.

Another explanation for the increase in null trials is the possibility that medical care and supportive therapy have improved since 2000. As a result it has become difficult to demonstrate treatment effects because new approaches must compete with higher quality medical care. In support of this argument is the observation that outcomes in cardiovascular diseases continue to improve despite wide variation in the specific care that patients receive. On the other hand, outcomes of studies that compared treatment to an active standard of care comparison group achieved results quite similar to studies that compared treatment to placebo. However, we do recognize that the quality of background cardiovascular care continues to improve, making it increasingly difficult to demonstrate the incremental value of new treatments. The improvement in usual cardiovascular care could serve as alternative explanation for the trend toward null results in recent years.

Our results may also reflect greater involvement by NHLBI in trial design and execution. Prior to 2000, most large NHLBI clinical trials were investigator initiatLaed while nearly 80% of the trials published after 2000 had direct involvement of NHLBI through cooperative agreements. We recognize that industry sponsored trials may have a higher success rate. It is possible that industry conducts trials designed to demonstrate effectiveness while NHLBI uses its resources when there is true equipoise.

All post 2000 trials reported total mortality while total mortality was only reported in about 80% of the pre-2000 trials and many of the early trials were not powered to detect changes in mortality. The effects on total mortality were null for both pooled analyses of trials that were registered or not registered prior to publication (see data in online supplement) In addition, prior to 2000 and the implementation of Clinicaltrials.gov, investigators had the opportunity to change the p level or the directionality of their hypothesis *post hoc*. Further, they could create composite variables by adding variables together in a way that favored their hypothesis. Preregistration in ClinicalTrials.gov essentially eliminated this possibility.

Limitations {#sec010}
-----------

Our analysis is limited to large NHLBI-funded trials and to studies on cardiovascular outcomes in adults. We focused on NHLBI because the Institute has championed transparency and allowed us full access to all trials. We emphasized large trials because we had access to outcomes of nearly all studies, thus reducing the risk of publication bias. Although we focused on cardiovascular trials, null results are common in other areas of medicine. For example, among 221 agents with the potential to modify outcomes for Alzheimer's disease, all placebo controlled trials registered in clinical trials.gov have failed to identify positive benefits on the declared primary outcome\[[@pone.0132382.ref007]\].

Our analysis underscores the importance of NHLBI involvement in trials. A greater number of recent trials used direct NHLBI, oversight. The institute is fully vetted for conflict of interest and applies high quality control standards including full transparency, open data access, and registration in ClincalTrials.gov. Our conclusions may not generalize to trials sponsored by industry or to other funding agencies.

We cannot say that trend toward null trials to preregistration in ClinicalTrials.gov is causal. Our analysis included only a small number of trials and the design of the study does not allow causal inferences. Most importantly, many variables may have changed around the year 2000. It is likely that other variables that are unknown or unmeasured also correspond to the decline in reports of significant therapeutic treatment effects.

Implications {#sec011}
------------

The transparency of RCTs is likely to have improved following the FDA Modernization Act of 1997, which created the ClinicalTrials.gov registry\[[@pone.0132382.ref008]\], a service that required registration of studies that test drugs, biologics, or devices for the treatment of serious or life threatening diseases\[[@pone.0132382.ref009]--[@pone.0132382.ref011]\]. Registered studies must provide: the study's purpose, recruitment status, design, eligibility criteria, locations and pre-specified primary and secondary outcomes\[[@pone.0132382.ref011]\]. The Consolidated Standards of Reporting Trials (CONSORT) were introduced in 1996 but expanded in 2001 to require greater transparency in the reporting of Randomized Clinical Trials (RCTs)\[[@pone.0132382.ref012]\]. Shortly after 2001, many major journals began requiring prospective registration of clinical trials as a condition for publication and the International Committee of Medical Journal Editors started requiring CONSORT reporting in all major journals beginning in 2004 (icjme.org). NHLBI was an early adopter of trial registration. All of their large trials published after 2000 were preregistered and transparently reported. Although we cannot say that stricter reporting requirements caused the trend toward more null reports from NHLBI trials, we do find the association worthy of more investigation.

In conclusion, null findings in large RCTs may be disappointing to investigators, but they are not negative for science. Properly powered trials might identify treatments that will improve public health. A growing collection of trials suggests that promising treatments do not match their potential when systematically tested and transparently reported. Publication of these trials may lead to the protection of patients from treatments that use resources while not enhancing patient outcomes. For example, a recent economic analysis of the Women's Health Initiative clinical trial suggested that the publication of the study may have resulted in 126,000 fewer breast cancer deaths, and 76,000 deaths from heart disease between 2003 and 2012. The economic analysis estimated that there was about \$140 returned for each dollar invested in the study\[[@pone.0132382.ref013]\]. Transparent and impartial reporting of clinical trial results will ultimately identify the treatments most likely to maximize benefit and reduce harm.
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